1. Connective Tissue Growth Factor Inhibition Enhances Cardiac Repair and Limits Fibrosis After Myocardial Infarction
- Author
-
Laura E. Vainio, MD, Zoltán Szabó, MSc, Ruizhu Lin, MSc, Johanna Ulvila, PhD, Raisa Yrjölä, MSc, Tarja Alakoski, MSc, Jarkko Piuhola, MD, PhD, Walter J. Koch, PhD, Heikki Ruskoaho, MD, PhD, Shaun D. Fouse, PhD, Todd W. Seeley, PhD, Erhe Gao, MD, PhD, Pierre Signore, PhD, Kenneth E. Lipson, PhD, Johanna Magga, PhD, and Risto Kerkelä, MD, PhD
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Summary: Myocardial infarction (MI)−induced cardiac fibrosis attenuates cardiac contractile function, and predisposes to arrhythmias and sudden cardiac death. Expression of connective tissue growth factor (CTGF) is elevated in affected organs in virtually every fibrotic disorder and in the diseased human myocardium. Mice were subjected to treatment with a CTGF monoclonal antibody (mAb) during infarct repair, post-MI left ventricular (LV) remodeling, or acute ischemia−reperfusion injury. CTGF mAb therapy during infarct repair improved survival and reduced LV dysfunction, and reduced post-MI LV hypertrophy and fibrosis. Mechanistically, CTGF mAb therapy induced expression of cardiac developmental and/or repair genes and attenuated expression of inflammatory and/or fibrotic genes. Key Words: connective tissue growth factor monoclonal antibody, fibrosis, heart failure, ischemia−reperfusion injury, left ventricle, myocardial infarction
- Published
- 2019
- Full Text
- View/download PDF